Evidence map›Paper›PMID 25798940›Full record

ArticlePloS one2015

Potent anti-proliferative, pro-apoptotic activity of the Maytenus royleanus extract against prostate cancer cells: evidence in in-vitro and in-vivo models.

Maria Shabbir, Deeba N Syed, Rahul K Lall, Muhammad Rashid Khan, Hasan Mukhtar

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
8.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Prostate cancer: Therapeutic prospect with herbal medicine.Current research in pharmacology and drug discovery · 2021
    Review
  7. Article
  8. The protective potential of aRSC advances · 2020
    Article
  9. Biomolecules · 2020
    Article
  10. Article
  11. Review
  12. Oxidative medicine and cellular longevity · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Protective effects of Fraxinus xanthoxyloides (Wall.) leaves against CClBMC complementary and alternative medicine · 2016
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Maria ShabbirDepartment of Dermatology, University of Wisconsin, Madison, Wisconsin, United States of America; Department of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan.
Deeba N SyedDepartment of Dermatology, University of Wisconsin, Madison, Wisconsin, United States of America.
Rahul K LallDepartment of Dermatology, University of Wisconsin, Madison, Wisconsin, United States of America; Department of Food Science, University of Wisconsin, Madison, Wisconsin, United States of America.
Muhammad Rashid KhanDepartment of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan.
Hasan MukhtarDepartment of Dermatology, University of Wisconsin, Madison, Wisconsin, United States of America.
University of Wisconsin–Madison · USQuaid-i-Azam University · PK

Funding

Developing Fisetin for the Managment of Prostate CancerR01CA160867 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA160867NCI NIH HHS R01CA160867
6 · The paper itself

Abstract

Prostate cancer is a leading of cause of cancer related death in men. Despite intensive investment in improving early diagnosis, it often escapes timely detection. Mortality remains high in advanced stage prostate cancer where palliative care remains the only option. Effective strategies are therefore needed to prevent the occurrence and progression of the disease. Plant-derived compounds have been an important source of several clinically useful anti-cancer agents and offer an attractive approach against prostate cancer. We previously showed that the methanol extract of Maytenus royleanus (MEM) leaves and its fractions possess significant antioxidant activity with therapeutic potential against free-radical associated damages. The present study evaluated the anti-proliferative activity of MEM in the prostate cancer model system. Analysis of MEM and its various fractions revealed the presence of triterpenoids, flavonoids and tannins, conjugated to one or more polar groups and carbohydrate moieties. Further studies against known standards established the existence of caffeic acid and quercetin 3-rhamnoside in varying concentration in different MEM fractions. Time course analysis of MEM treated prostate cancer cells indicated significant decrease in cell viability, assessed by MTT and clonogenic survival assays. This was accompanied by G2 phase arrest of cell cycle, downregulation of cyclin/cdk network and increase in cdk inhibitors. MEM treated cells exhibited cleavage of Caspase-3 and PARP, and modulation of apoptotic proteins, establishing apoptosis as the primary mechanism of cell death. Notably MEM suppressed AR/PSA signaling both in prostate cancer cell cultures and in the in vivo model. Intraperitoneal injection of MEM (1.25 and 2.5 mg/ animal) to athymic nude mice implanted with androgen sensitive CWR22Rν1 cells showed significant inhibition in tumor growth and decreased serum PSA levels reciprocating in vitro findings. Taken together, our data suggest that MEM may be explored further for its potential therapeutic effects against prostate cancer progression in humans.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBlotting, WesternCaspasesCell CycleCell ProliferationCell SurvivalEnzyme-Linked Immunosorbent AssayHumansImmunoenzyme TechniquesIn Vitro TechniquesMaleMaytenusMiceMice, NudeAntineoplastic AgentsCaspasesPlant ExtractsRNA, Messenger

Identifiers

PMID25798940
PMCPMC4370495
OpenAlexW2052431558

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.